pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
← back to Silence Therapeutics plc
News mentioning $SLN
11
stories
23d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
29d
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
biopharma dive
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 11, 26
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
Aug 10, 26
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
Aug 10, 26
STAT+: FDA panel to weigh Grail’s Galleri test
stat
Aug 10, 26
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
Aug 10, 26
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
Aug 10, 26
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
Aug 10, 26
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
stat
Aug 10, 26
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
Silence Therapeutics plc ($SLN) · news · pharmadog
